<DOC>
	<DOCNO>NCT02106195</DOCNO>
	<brief_summary>The primary objective ass safety tolerability 200 mg KD025 administer orally daily 28 day</brief_summary>
	<brief_title>A Safety Tolerability Study KD025 Treatment Subjects With Moderately Severe Psoriasis Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Diagnosis moderately severe plaque psoriasis stable 6 month fail least one line systemic therapy candidate additional systemic therapy . Had PASI ≥12 At least 10 % body surface area affect plaque psoriasis . Willing avoid tanning device sun bath . Willing forgo systemic topical treatment psoriasis course study . Adequate bone marrow function Negative urine pregnancy test ( woman childbearing potential ) Agree use highly effective method birth control ( &lt; 1 % per year failure rate ) study 1 month termination study . Willing complete study measurement assessment compliance protocol . Nonplaque druginduced psoriasis Currently use corticosteroid immunosuppressive therapy except Class 5 weak topical corticosteroid face , groin , scalp Using topical therapy except follow : 1 . Class 5 weaker steroid phototherapy 4 week prior study entry 2 . Immunosuppressive therapy 4 week prior study entry 3 . Methotrexate , acitretin , cyclosporine 4 week prior study entry 4 . Biologic therapies 3 month prior study entry . Concomitant condition require treatment moderate high dose steroid 12 week prior screen . Viral , fungal , bacterial skin infection . Pregnant lactate woman . Currently participate another study investigational drug within 28 day study entry History evidence severe illness condition would make subject , opinion investigator , unsuitable study History presence following : 1 . Hepatic disease alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 1.5 × upper limit normal ( ULN ) screen 2 . Renal disease and/or serum creatinine &gt; 1.5xULN screening Has QTc ( f ) interval &gt; 450 msec screen predose ECG Subject receive drug know prolong QTc interval , include antiarrhythmic medication within 2 week prior screen Subject receive drug strong CYP enzyme inhibitor Subject receive concomitant systemic drug metabolize CYP enzyme Previous exposure KD025 know allergy/sensitivity KD025 ROCK2 inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>